References
- Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators of Inflammation. 2015; 2015:145293.
- Pizzi M, Croci GA, Ruggeri M et al. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases. Cancers (Basel). 2021 Nov 12; 13(22):5666.
- Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008 May; 22(5):905-14.
- Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016 Apr; 30(4):776-81.
- Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012 May; 87(5):552-4.
- Kerdoud O, Aloua R, Kaouani A, Belem O, Slimani F. Squamous cell carcinoma during long term hydroxyurea treatment: A case report. Int J Surg Case Rep. 2021 Aug; 85:106160.
- Hultdin M, Sundström G, Wahlin A, Lundström B, Samuelsson J, Birgegård G, Engström-Laurent A. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med Oncol. 2007; 24(1):63-70.
- Bieniaszewska M, Sobieralski P, Leszczyńska A, Dutka M. Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. Leuk Res. 2022 Dec; 123:106962.
- Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al; PROUD-PV Study Group. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020 Mar; 7(3):e196-e208. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25;
- Okikiolu J, Woodley C, Cadman-Davies L, O’Sullivan J, Radia D, Garcia NC et al. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep. 2022 Dec 16; 19:100360.
- Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P et al. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study. Haematologica. 2018 Mar; 103(3):438-446.
- Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res. 2017 Mar; 54:73-77.
- Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023 Jan 19; 13:1109866.
- Verstovsek S, Komatsu N, Gill H, Jin J,Lee SE, Hou HA et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.
- Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175. Epub 2017 Mar 11. Erratum in: Lancet Haematol. 2017 Jun; 4(6):e257.